beta-thujaplicinol has been researched along with HIV in 1 studies
*HIV: Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, X; Daelemans, D; De Clercq, E; Ding, X; Dong, G; Gao, P; Liu, X; Menéndez-Arias, L; Pannecouque, C; Sun, L; Wang, X; Zhan, P; Zhang, X | 1 |
1 other study(ies) available for beta-thujaplicinol and HIV
| Article | Year |
|---|---|
5-Hydroxypyrido[2,3-b]pyrazin-6(5H)-one derivatives as novel dual inhibitors of HIV-1 reverse transcriptase-associated ribonuclease H and integrase.
Topics: Anti-HIV Agents; Dose-Response Relationship, Drug; HIV; HIV Integrase; HIV Integrase Inhibitors; Microbial Sensitivity Tests; Molecular Structure; Pyrazines; Reverse Transcriptase Inhibitors; Ribonuclease H; Structure-Activity Relationship | 2018 |